Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

被引：0
|
作者：
Inga-Marie Schaefer
Matthew L. Hemming
Meijun Z. Lundberg
Matthew P. Serrata
Isabel Goldaracena
Ninning Liu
Peng Yin
Joao A. Paulo
Steven P. Gygi
Suzanne George
Jeffrey A. Morgan
Monica M. Bertagnolli
Ewa T. Sicinska
Chen Chu
Shanshan Zheng
Adrian Mariño-Enríquez
Jason L. Hornick
Chandrajit P. Raut
Wen-Bin Ou
George D. Demetri
Sinem K. Saka
Jonathan A. Fletcher
机构：
[1] Harvard Medical School,Department of Pathology, Brigham and Women’s Hospital
[2] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology
[3] Dana-Farber Cancer Institute and Brigham and Women’s Hospital,Sarcoma Center
[4] Harvard University,Wyss Institute for Biologically Inspired Engineering
[5] Harvard Medical School,Department of Cell Biology
[6] Brigham and Women’s Hospital,Department of Surgery
[7] Harvard Medical School,Department of Pathology
[8] Dana-Farber Cancer Institute,Department of Cancer Biology
[9] Harvard Medical School,Department of Genetics
[10] Dana-Farber Cancer Institute,Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine
[11] Blavatnik Institute,Ludwig Center at Harvard
[12] Harvard Medical School,European Molecular Biology Laboratory (EMBL)
[13] Zhejiang Sci-Tech University,undefined
[14] Harvard Medical School,undefined
[15] Genome Biology Unit,undefined
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2072 / 2085
页数：13
相关论文
共 50 条
  • [41] Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
    Rihani, Ali
    Vandesompele, Jo
    Speleman, Frank
    Van Maerken, Tom
    CANCER CELL INTERNATIONAL, 2015, 15
  • [42] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [43] MGMT inhibition leads to CDK4/6 inhibition and enhances palbociclib and abemaciclib activity in breast cancer
    Bobustuc, George C.
    Kassam, Amin B.
    Rovin, Richard A.
    Donohoe, Deborah L.
    Albiero, Maxwell
    Jella, Tarun
    Fukui, Olivia
    Piron, Cameron
    Konduri, Santhi D.
    CANCER RESEARCH, 2017, 77
  • [44] Cdk2 and Cdk4 cooperatively control the expression of Cdc2
    Berthet, Cyril
    Kaldis, Philipp
    CELL DIVISION, 2006, 1 (1)
  • [45] Cdk2 and Cdk4 cooperatively control the expression of Cdc2
    Cyril Berthet
    Philipp Kaldis
    Cell Division, 1
  • [46] CDK4/CDK6 inhibition radiosensitises HPV-neg HNSCC through inhibition of homologous recombination
    Gottgens, E.
    Leszczynska, K.
    Bussink, J.
    Hammond, E.
    Span, P.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S129 - S130
  • [47] Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers
    Zhou, Feng
    Yang, Guimei
    Tang, Feng
    Zhang, Yan
    Yang, Wenqing
    Xue, Liting
    Chen, Ping
    Tang, Renhong
    CANCER RESEARCH, 2022, 82 (12)
  • [48] Inhibition cyclin dependent kinase 4 (CDK4) activity by thiazolidinones
    Pallela, Venkat R.
    Natala, Srinivas R.
    Cosenza, Stephen C.
    Mallireddigari, Muralidhar R.
    Pappathi, Nabissa
    Akula, Balaiah
    Billa, Vinaykumar
    Reddy, E. Premkumar
    Reddy, MV. Ramana
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [49] Investigating the effect of CDK4/6 and MDM2 inhibition on melanoma
    Slesur, Lauren
    Vilgelm, Anna
    Al-Rohil, Rami
    Richmond, Ann
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [50] CDK4 inhibition enhances anti-melanoma effects of BRAF/MEK inhibition
    Zhang, Yanping
    Hsueh, Eddy C.
    CANCER RESEARCH, 2017, 77
12345